ThalesNano and ETH Zurich Collaborate on Flow Chemistry Technologies
News Oct 30, 2007
ThalesNano has announced collaboration with the Swiss Federal Institute of Technology Zurich (ETH Zurich) on flow chemistry applications. The agreement will focus on the application of chemistries and technologies utilizing ThalesNano's products to solve difficult chemistry applications.
Dr. Laszlo Urge, CEO of ThalesNano Inc., said "We are extremely pleased to be able to collaborate with one of the top research universities in the world. This collaboration will enable us to utilize our technology and to jointly develop novel applications that will serve the entire scientific community. Our products are in use at all major pharmaceutical, agrochemical and chemistry companies and also support in-house scientists in developing their own novel applications. The technology developed as part of this collaboration may result in spin-off opportunities in future."
Professor Peter Seeberger whose laboratory at ETH Zurich is leading the project said "We are delighted to have this collaboration with the foremost company in flow chemistry instrument and application development. This is a very exciting area of technology, and in it we anticipate being able to contribute to the development of novel chemistries. There are a lot of scientific and technical advantages in this field. We are looking forward to the combined exploration."
Tuberculosis (TB), an ancient and notoriously difficult disease to treat, has killed millions through the course of human history; and the antibiotics that have been used to fight the disease in recent history are becoming less and less effective. In the face of this reality, researcher Prof. Dennis Wright has improved upon a new way to thwart the tricky pathogen, mycobacterium tuberculosis.READ MORE
Researchers have solved the structures of the cancer-promoting enzymes USP25 and USP28, and identified significant differences in their activities. This knowledge provides the molecular basis for the development of new and highly specific anti-cancer drugs, with a low risk of side-effects.READ MORE